Introduction
Lamotrigine (LTG) is the most commonly administered secondline antiepileptic-drugs (ADEs) and is also effective in the treatment of a variety of other abnormalities of neuronal excitability, including bipolar disorder [1, 2] , and neuropathic pain [3] . However, 10% of subjects in controlled trials are allergic to LTG and are susceptible to a wide spectrum of adverse cutaneous clinical manifestations including extremely painful and life-threatening conditions [4] .
Skin reactions are a common side effect of antiepileptic drugs (AEDs) and a major cause of treatment discontinuation. The clinical spectrum of these reactions is wide. Most skin reactions are common and mild maculopapular rashes that disappear within a few days after discontinuing drug use. Benign rashes are relatively common with aromatic AEDs, such as carbamazepine (CBZ), phenytoin (PHT), and phenobarbital (PB), with a frequency ranging from 5 to 15% of treated individuals. Some of the newer drugs also frequently cause skin rashes, particularly lamotrigine (LTG), and oxcarbazepine (OXC).
The incidence of rash is now well recognized to be dose-and titration-dependent, and is related with concomitant therapy with valproic acid (VPA). Since the introduction of a gradual titration schedule in 1994, the rate of severe rashes with LTG has declined from 1 to 0.1-0.01 percent [5] . However, there was not a substantial reduction observed in the rate of benign rashes, which has still remained between 8 and 11 percent [6] .
Although LTG has been used in everyday clinical practice for nearly 25 years and the possibility of rash is now routinely managed, it is still not clearly known whether LTG increases the risk of developing a skin rash compared to other drugs. Here, we systematically reviewed published studies to provide current evidence on the incidence of LTG related skin rashes and compared this risk with other drugs.
Methods

Search strategy
We searched the PubMed (data from 1990 to March 2014), and Scopus (up to March 2014) databases for relevant studies. The search terms used were: ''lamotrigine'', ''lamictal'', ''rash'', and ''skin reaction''. Studies were limited to human studies and were published in English.
A cutaneous adverse reaction was defined as any types of rash (erythematous, maculo-papular, papular, pustular or unspecified) that could only be caused by an antiepileptic drug effect and that resulted in contacting a physician.
Selection criteria
To determine the practical significance of the study, we evaluated the incidence and the risk of developing a skin rash in patients who received LTG therapy. Thus, we included multiple dose levels of LTG treatment. We included all prospective, retrospective and postmarketing studies reporting a skin rash with LTG therapy. Clinical trials that met the following criteria were included in the meta-analysis: (1) prospective randomized controlled trials or open-label trials of patients receiving LTG treatment and its presence with a control group; (2) retrospective study, which included the data of LTG related rashes and could be compared with other drugs.
We excluded reviews, editorials, single cases and case series, studies published only as abstracts, letters, or commentaries and studies they were a part of duplicate populations. For the metaanalysis, on the basis of the inclusion and exclusion criteria, we identified a total of 21 prospective case-controlled studies (1 study involving Asian subjects and 20 involving European-Caucasian subjects) (Table 1) , and 6 retrospective studies (2 studies involving Asian subjects and 4 studies involving European-Caucasian subjects) ( Table 2 ).
Data extraction and quality assessment
We designed and piloted a standardized data abstraction form to capture all of the relevant study-level information required for analysis. Two independent investigators performed the data extraction (W.X.Q. and X.J.), and any discrepancy between the reviewers was resolved by consensus. For each study, the following information was obtained: the author's name, year of publication, trial phase, number of enrolled subjects, treatment arms, number of patients in the treatment and control groups when available, median age, median treatment duration, and adverse outcomes of interest (skin rash).
Statistical analysis
All of the analyses were performed using STATA 12.0 (StataCorp, College Station, Texas, USA). A p-value of less than 0.05 was considered statistically significant, and all of the tests were two-sided. The crude odds ratios (ORs) and 95% confidence intervals (CIs) were used to express the risk of skin rash with LTG therapy compared with other drugs. Forest plots were used to depict the visual representation of the meta-analysis results. Metaanalysis was performed using fixed-effects [7] or random-effects [8] models. Heterogeneity was tested using w 2 -based Cochran's Q statistic [9] and I 2 metric statistics [10] . Random-effects models were used only when there was considerable heterogeneity (P < 0.05 or I 2 > 50% among the studies).
Studies were classified according to the study type (prospective study, retrospective study and postmarketing reports). In the first two group, all of the crude OR calculated by the original data were pooled. We performed the analyses on only the observed crude rate estimates, primarily because there was no study that reported adjusted estimates. We also performed the following specified subgroup analyses: different control groups (placebo, other antiepileptic drugs, or other antidepressive drugs), different groups of patients (epilepsy, bipolar or patients with neuropathic pain), prospective study, and retrospective study.
Results
Study selection and characteristics
Our search yielded 748 records describing the use of LTG and a skin rash from the Pubmed and Scopus databases. The selection process is summarized in Fig.1 . After the exclusion of duplicate studies and a review of the abstracts, a total of 94 human clinical studies were identified with information on LTG therapy and benign rashes. Full-text articles were retrieved for these records and carefully studied. Finally, in the prospective studies, a total of 26 studies involving LTG-induced rash were used to evaluate rash incidence and 21 articles with controls fulfilling the inclusion and exclusion criteria were identified for meta-analysis (Fig.1 and Table 1 ). In this group, 4447 patients receiving LTG treatment were investigated, including a variety of diseases: epilepsy (13 trials) [15, 16, [23] [24] [25] [26] [27] [28] [29] [30] 33, 34, 36] , dipolar disorder (9 trials) [17] [18] [19] [20] [21] [22] 31, 32, 35] , and neuropathic pain (1 magraine [11] , 1 multiple sclerosis [12] , 1 HIV-related [13] , and 1 diabetic [14] ). The sample sizes were within the range of 20-958 patients with LTG. The median age of study participants was 9.6-77 years.
In the retrospective studies, 8 articles were used to evaluate rash incidence [37] [38] [39] [40] [41] [42] [43] [44] and 6 studies fulfilling the inclusion criteria were identified for meta-analysis [37] [38] [39] [40] [41] [42] , which were all derived from epileptic studies ( Fig.1 and Table 2 ). The sample sizes were within the range of 8-1037 patients treated with LTG. Two articles were pediatric studies, of which one study included all age groups and 5 studies included patients older than 12 years.
There were 5/7 postmarketing studies that provided data on the skin rash incidence of LTG [45] [46] [47] 49, 50] (Table 3) . Four studies were performed in the U.K., which were performed by Prescription-Event Monitoring (PEM) to establish the safety of LTG and other drugs, in which the entire population of prescriptions issued was accessible [45] [46] [47] 50] . One study was performed in Germany [49] , where the data were obtained from a database of 208,401 psychiatric inpatients who were monitored by the Safety surveillance project Drug Safety in Psychiatry from 1993 to 2005, which surveys clinically relevant adverse reactions to all marketed psychotropic drugs. One report was performed in Sweden [51] , which aimed to determine the extent of the spontaneous reporting of ADRs in children. One study was on the safety profile of antiepileptic drugs in Italy [48] , from January 1988 to June 2005. Only 2/7 of these studies followed cohorts of more than 10,000 subjects [45, 49] .
Incidence of skin rash
The overall incidence of skin rash with LTG treatment was 9.98% (444/4447) from 26 prospective clinical trials, 7.19% (214/2977) from 8 retrospective studies, and 2.09% (547/26,126) from 5 postmarketing reports. (Fig.2) . We did not perform a sensitivity analysis, and we studied the published bias to examine the stability and reliability of pooled OR of LTG-related skin rashes by the sequential omission of individual studies due to the small number of studies in each group.
Meta-analysis from retrospective studies
All 6 retrospective studies were epileptic studies. (Fig.3) .
There was no significant difference in the rash risk between patients with LTG and aromatic AEDs [CBZ (6 studies (Fig.4) . Due to the small number of studies in each group, we did not perform a sensitivity analysis, and we studies the published bias to examine the stability and reliability of pooled OR of LTG-related skin rash.
Furthermore, in prospective studies, we observed a low heterogeneity when studying LTG with placebo in epileptic patients, with placebo or lithium in bipolar patients, and with non-aromatic AEDs (I 2 = 0%, 7.4%, 0%, 8.3%, respectively). However, a considerable heterogeneity of more than 50% was observed in cases of placebo in patients with neuropathic pain and aromatic AEDs (I 2 = 59.9%, 54.7%, respectively).
In retrospective studies, we observed a low heterogeneity when studying the LTG with OXC, PHT, VPA, GBP, LEV, and ZNS (I 2 = 0%, 0%, 0%, 5%, 0%, 0%, respectively). However, a considerable heterogeneity of more than 50% was observed in cases of CBZ, TPM (I 2 = 69.8%, 65.2%, respectively).
Discussion
Our estimates showed that the overall incidence of skin rash with LTG therapy was 9.98% from prospective studies, 7.19% from retrospective studies, and 2.09% from postmarketing reports. The prospective study results were consistent with the previous pooled prospective data for 3348 patients from placebo-controlled and open trials of LTG in adults, which showed that 10% of patients exposed to LTG developed a rash [52, 53] .
This incidence is lower in retrospective studies compared to prospective studies, which indicates a limitation in this type of study. A retrospective study usually underestimates the true incidence due to recall bias or a physician bias when determining whether a specific rash is related to a given medication.
The postmarketing studies use relatively different methods from prospective trials or retrospective studies, which were performed by a spontaneous report or Prescription-Event Monitoring (PEM) to establish the safety of LTG and other drugs. There were four studies performed in the U.K., one study performed in Germany, one study performed in Italy, and one study performed in Sweden. The Drug Safety Research Unit (DSRU) performed PEM [54, 55] of newly marketed drugs with widespread use in general practice in England, particularly with drugs that are intended for long-term use. However, systematic postmarketing surveillance of AEDs is still generally lacking, and large-scale postmarketing surveillance was performed to assess the safety of LTG in U.K. [45] [46] [47] 50] .
The main weakness of comparative PEM analysis is the potential for bias to confound differences between drugs [54, 55] . Underreporting is a main disadvantage because the absolute number of ADR reports is not truly known. Data obtained from spontaneous reports or PEM when taken alone do not accurately quantify the risk associated with a drug. The reporting rate may vary over time and be influenced by factors, such as media attention. Although such studies cannot eliminate bias as effectively as RCTs, their strength lies where the RCT is often weakest, in providing a large number of patients from whom relative discontinuation rates can be precisely estimated.
In this meta-analysis of 21 prospective studies, we did not find a significant difference between patients with LTG and other drugs, including placebo, other ADEs and lithium (OR 0.99-2.41).
In 6 respective studies, there was a significantly higher OR in patients with LTG compared with non-aromatic AEDs, which indicated that LTG treatment might significantly increase the risk of developing skin rash compared to non-aromatic AEDs. There was no significant different in rash risk between patients with LTG and aromatic AEDs, except PB. Due to few prospective control studies, we did not determine whether this merely reflected a publication bias or whether the risk of skin rash with LTG therapy is truly not higher compared to other aromatic AEDs or placebo.
Epilepsy is a serious chronic brain disorder that is characterized by recurrent unprovoked seizures that can be successfully treated and controlled using mono-or polytherapy in most patients. Skin reactions are a common side effect of AEDs and a major cause of treatment discontinuation [56] . Benign rash is relatively common with aromatic AEDs, such as CBZ, PHT and PB, with a frequency ranging from 5% to 15% of treated individuals. In addition, several newer drugs also frequently cause skin rashes, particularly LTG and OXC. Wang et al. [57] reported that skin reactions were three times more frequent with aromatic AEDs compared to non-aromatic AEDs.
Reliability of the study
There are several limitations to this study. First, the number of studies that addressed skin rashes with LTG therapy is small, in which only 4447 patients with LTG treatment from 26 prospective studies and 2977 patients from 8 retrospective studies were included in this study. A few studies have reported serious lifethreatening rashes; however, we could not obtain the incidence of a serious rash. Second, different study designs, treatment strategies, durations and concomitant administration of drugs contribute to an increase in the clinical heterogeneity of the metaanalysis, which make the interpretation of the meta-analysis more problematic. Third, the data did not allow us to perform multivariable regression to determine which variables were independently related with LTG-induced skin rash, including the LTG titration speed and cotreatment with VPA. Forth, it was not possible to use narrower age categories because the studies provided either overall estimates or age-specific estimates with different age categories. Finally, we could not perform a publication bias test in our review because the meta-analyses in each group were less than 10 studies, which are considered the baseline number for testing publication bias. Nevertheless, despite these limitations, our study provides a platform for vast heterogeneous data in studies exploring the risk of LTG-induced skin rash under a common roof and provides some important insights.
Conclusion
On the basis of the findings of the present study and the existing literature, the overall incidence of skin rash with LTG therapy was 9.98% from prospective studies, 7.19% from retrospective studies, and 2.09% from postmarketing reports. These data could potentially be used to assess the burden and analyze the risk of developing a skin rash in patients with LTG therapy. Our results showed that LTG significantly increased the risk of developing a skin rash compared to non-aromatic AEDs. Taken together, these results support the need for large prospective population-based studies and clinical trials to confirm whether LTG increases the risk of developing a skin rash compared to other drugs.
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